title: Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee.
abstract: Recombinant adenovirus type 4, 5, and 7 expressing the fusion glycoprotein (F) gene, the attachment glycoprotein (G) gene, or both F and G genes of respiratory syncytial virus (RSV) was constructed. Intratracheal immunization of dogs with Ad7F induced moderate titers of RSV-neutralizing antibodies. After booster immunization with Ad4F, the dogs developed high titers of RSV-specific antibody. Subsequently, three two-dose vaccination regimens, Ad4F/Ad5F, Ad7G/Ad4G, and Ad7FG/Ad4FG, were compared with Ad7F/Ad4F for immunogenicity and protective efficacy. The results indicated that Ad4F/Ad5F was equal or greater in immunogenicity to Ad7F/Ad4F, but Ad7G/Ad4G and Ad7FG/Ad4FG were less effective than Ad7F/Ad4F in inducing RSV-neutralizing antibody. All vaccination regimens completely protected the lungs of dogs from RSV infection. A chimpanzee was sequentially immunized orally with Ad7F, Ad4F, and Ad5F. A low-level antibody response to RSV was induced after the primary immunization, but no significant increases were observed after booster immunizations.
authors.affiliation: Division of Biotechnology and Microbiology, Wyeth-Ayerst Research, Philadelphia, Pennsylvania 19101.
authors.forename: K H
authors.initials: KH
authors.lastname: Hsu
authors.forename: M D
authors.initials: MD
authors.lastname: Lubeck
authors.forename: A R
authors.initials: AR
authors.lastname: Davis
authors.forename: R A
authors.initials: RA
authors.lastname: Bhat
authors.forename: B H
authors.initials: BH
authors.lastname: Selling
authors.forename: B M
authors.initials: BM
authors.lastname: Bhat
authors.forename: S
authors.initials: S
authors.lastname: Mizutani
authors.forename: B R
authors.initials: BR
authors.lastname: Murphy
authors.forename: P L
authors.initials: PL
authors.lastname: Collins
authors.forename: R M
authors.initials: RM
authors.lastname: Chanock
mesh_terms: D000260:Adenoviruses, Human / Q000235:genetics / Q000276:immunology*; D000818:Animals; D000914:Antibodies, Viral / Q000276:immunology; D000956:Antigens, Viral / Q000008:administration & dosage / Q000235:genetics* / Q000276:immunology; D004285:Dogs; D004334:Drug Administration Schedule; D015707:HN Protein; D009500:Neutralization Tests; D002679:Pan troglodytes; D012136:Respiratory Syncytial Viruses / Q000235:genetics / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000517:prevention & control; D010253:Respirovirus Infections / Q000517:prevention & control; D014611:Vaccination; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D014764:Viral Proteins; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; D000956:Antigens, Viral; D015707:HN Protein; D014759:Viral Envelope Proteins; D014760:Viral Fusion Proteins; D014764:Viral Proteins; D014765:Viral Vaccines; C116204:attachment protein G